122 in preclinical development
92 in human trials
Vaccine CANDIDATES
Legend
  ↓/↑ | Name  ↓/↑ | Organization  ↓/↑ | Technology  ↓/↑ | Stage  ↓ | Countries  ↓/↑ | Clinical Trial # | ||
---|---|---|---|---|---|---|---|---|
Shenzhen Geno-Immune Medical Institute | Modified APC | Phase I/II | ![]() | NCT04276896 | ||||
Multiple Organizations | RNA-based vaccine | Phase I/II/III/IV | ![]() | NCT04283461 and 12 more | ||||
Multiple Organizations | Non-replicating viral vector | Phase I/II/III | ![]() ![]() | NCT04313127 and 8 more | ||||
Multiple Organizations | Inactivated virus | Phase I/II/III/IV | ![]() | NCT04352608 and 17 more | ||||
Multiple Organizations | DNA-based | Phase I/II/III | ![]() | NCT04336410 and 2 more | ||||
Multiple Organizations | Inactivated virus | Phase I/II/III | ![]() | ChiCTR2000031809 and 3 more | ||||
Multiple Organizations | Inactivated virus | Phase I/II/III | ![]() | ChiCTR2000032459 and 4 more | ||||
Multiple Organizations | DNA-based | Phase I | ![]() | NCT04334980 | ||||
updated | Multiple Organizations | RNA-based vaccine | Phase I/II/III/IV | ![]() ![]() | EudraCT 2020-001038-36 and 23 more | |||
Novavax, Takeda | Protein subunit | Phase I/II/III | ![]() | NCT04368988 and 5 more | ||||
Shenzhen Geno-Immune Medical Institute | Modified APC | Phase I | ![]() | NCT04299724 | ||||
Unnamed | Saiba GmbH | Virus Like Particle | Preclinical Phase | |||||
Medicago Inc. | Virus Like Particle | Phase I/II/III | ![]() | NCT04450004 and 2 more | ||||
Unnamed | Imophoron Ltd, Bristol University's Max Planck Centre | Virus Like Particle | Preclinical Phase | |||||
Unnamed | Doherty Institute | Virus Like Particle | Preclinical Phase | |||||
Unnamed | Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile* | Unknown | Preclinical Phase | |||||
Unnamed | Emergex Vaccines, George Mason University's National Center for Biodefense and Infectious Diseases (NCBID)* | Unknown | Preclinical Phase | |||||
Unnamed | VBI Vaccines, National Research Council of Canada | Unknown | Preclinical Phase | |||||
Unnamed | SmartPharm Therapeutics, Sorrento Therapeutics | Unknown | Preclinical Phase | |||||
Unnamed | HaloVax (Voltron Therapeutics), The Vaccine & Immunotherapy Center at the Massachusetts General Hospital | Unknown | Preclinical Phase | |||||
Unnamed | ISR Immune System Regulation | Unknown | Preclinical Phase | |||||
Unnamed | ImmunoPrecise | Unknown | Preclinical Phase | |||||
Unnamed | Tulane University | Unknown | Preclinical Phase | |||||
Unnamed | SK Biosciences | Unknown | Preclinical Phase | |||||
Unnamed | Vir Biotechnology, GSK | Unknown | Preclinical Phase | |||||
Unnamed | Precision Vaccines Program at Boston Children's Hospital | Unknown | Preclinical Phase | |||||
Kentucky BioProcessing, Inc. | Protein subunit | Phase I/II | ![]() ![]() | NCT04473690 | ||||
Unnamed | Universite Laval | Unknown | Preclinical Phase | |||||
Multiple Organizations | Protein subunit | Phase I/II/III | ![]() ![]() | NCT04545749 and 2 more | ||||
Unnamed | Multiple Organizations | RNA-based vaccine | Preclinical Phase | |||||
Unnamed | Multiple Organizations | RNA-based vaccine | Preclinical Phase | |||||
Unnamed | Centro Nacional Biotecnologia (CNB-CSIC), Spain | RNA-based vaccine | Preclinical Phase | |||||
Unnamed | University of Tokyo, Daiichi-Sankyo | RNA-based vaccine | Preclinical Phase | |||||
Unnamed | Multiple Organizations | RNA-based vaccine | Preclinical Phase | |||||
Arcturus Therapeutics, Inc., Duke-NUS | RNA-based vaccine | Phase I/II | ![]() ![]() | NCT04480957 and 2 more | ||||
Imperial College London, Morningside Ventures | RNA-based vaccine | Phase I/II | ![]() ![]() | IRAS-Number: 279315 and 1 more | ||||
CureVac AG, Coalition for Epidemic Preparedness Innovations (CEPI) | RNA-based vaccine | Phase I/II/III | ![]() | NCT04449276 and 3 more | ||||
Unnamed | Multiple Organizations | RNA-based vaccine | Preclinical Phase | |||||
Unnamed | BIOCAD | RNA-based vaccine | Preclinical Phase | |||||
Unnamed | Multiple Organizations | RNA-based vaccine | Preclinical Phase | |||||
Unnamed | GeneOne Life Science, Houston Methodist | RNA-based vaccine | Preclinical Phase | |||||
Unnamed | Zydus Cadila | Replicating viral vector | Preclinical Phase | |||||
Multiple Organizations | Replicating viral vector | Phase I | ![]() | NCT04497298 | ||||
Unnamed | Multiple Organizations | Protein subunit | Preclinical Phase | |||||
Unnamed | ExpreS2ion | Protein subunit | Preclinical Phase | |||||
Unnamed | WRAIR, USAMRIID | Protein subunit | Preclinical Phase | |||||
Unnamed | National Institute of Infectious Disease, Japan | Protein subunit | Preclinical Phase | |||||
Unnamed | Sanofi Pasteur, Translate Bio | RNA-based vaccine | Preclinical Phase | |||||
Multiple Organizations | Protein subunit | Phase I/II/III | ![]() | NCT04405908 and 1 more | ||||
Unnamed | Vaxil Bio | Protein subunit | Preclinical Phase | |||||
Unnamed | Biological E Ltd | Protein subunit | Preclinical Phase | |||||
Unnamed | AJ Vaccines | Protein subunit | Preclinical Phase | |||||
Unnamed | Multiple Organizations | Protein subunit | Preclinical Phase | |||||
Unnamed | Generex, EpiVax | Protein subunit | Preclinical Phase | |||||
Unnamed | EpiVax, University of Georgia | Protein subunit | Preclinical Phase | |||||
PittCoVacc | University of Pittsburgh | Protein subunit | Preclinical Phase | ![]() | ||||
Unnamed | Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan | Protein subunit | Preclinical Phase | |||||
Unnamed | Multiple Organizations | Protein subunit | Preclinical Phase | |||||
Sanofi Pasteur, GlaxoSmithKline | Protein subunit | Phase I/II | ![]() | NCT04537208 and 1 more | ||||
Unnamed | Heat Biologics (Zolovax), University of Miami | Protein subunit | Preclinical Phase | |||||
Multiple Organizations | Protein subunit | Phase I | ![]() | ACTRN12620000674932 and 1 more | ||||
Unnamed | Baylor College of Medicine | Protein subunit | Preclinical Phase | |||||
Unnamed | iBio, CC-Pharming | Protein subunit | Preclinical Phase | |||||
Unnamed | St. Petersburg Scientific Research Institute of Vaccines and Serums | Protein subunit | Preclinical Phase | |||||
Unnamed | VIDO-InterVac, University of Saskatchewan | Protein subunit | Preclinical Phase | |||||
Unnamed | Flow Pharma | Protein subunit | Preclinical Phase | |||||
Unnamed | University of Cambridge, DIOSynVax | Protein subunit | Preclinical Phase | |||||
Unnamed | OncoGen | Protein subunit | Preclinical Phase | |||||
Unnamed | MIGAL Galilee Research Institute | Protein subunit | Preclinical Phase | |||||
Unnamed | University of Alberta | Protein subunit | Preclinical Phase | |||||
DPX-COVID-19 | IMV, Inc. / Canadian Center for Vaccinology at Dalhousie University / Izaak Walton Killam Health Center/ Nova Scotia Health Authority, Canadian Immunization Research Network / University of Laval / Global Urgent and Advanced Research and Development in Canada | Protein subunit | Preclinical Phase | ![]() | ||||
Unnamed | GeoVax, BravoVax | Non-replicating viral vector | Preclinical Phase | |||||
updated | Multiple Organizations | Non-replicating viral vector | Phase I/II/III | ![]() | NCT04436276 and 7 more | |||
Unnamed | ReiThera | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | ImmunityBio, NantKwest | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | DZIF - German Center for Infection Research | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | Greffex | Non-replicating viral vector | Preclinical Phase | |||||
Vaxart | Non-replicating viral vector | Phase I | ![]() | NCT04563702 | ||||
Unnamed | Centro Nacional Biotecnologia (CNB-CSIC), Spain | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | University of Manitoba | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | DZIF - German Center for Infection Research | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | Tonix Pharma, Southern Research | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | BIOCAD, IEM | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | IAVI, Batavia | Non-replicating viral vector | Preclinical Phase | |||||
AdCOVID | Altimmune, University of Alabama at Birmingham | Non-replicating viral vector | Preclinical Phase | ![]() | ||||
Unnamed | University of Western Ontario | Non-replicating viral vector | Preclinical Phase | |||||
Unnamed | Valneva, Dynavax* | Inactivated virus | Preclinical Phase | |||||
Unnamed | Sinovac, Dynavax | Inactivated virus | Preclinical Phase | |||||
Unnamed | Multiple Organizations | Inactivated virus | Preclinical Phase | |||||
Unnamed | Codagenix, Serum Institute of India | Inactivated virus | Preclinical Phase | |||||
CoroFlu | Multiple Organizations | Inactivated virus | Preclinical Phase | ![]() ![]() | ||||
Unnamed | Multiple Organizations | DNA-based | Preclinical Phase | |||||
Unnamed | OPENCORONA - Cobra Biologics, Karolinska Institute | DNA-based | Preclinical Phase | |||||
Unnamed | The University of Hong Kong | Non-replicating viral vector | Preclinical Phase | |||||
AnGes, Inc., Japan Agency for Medical Research and Development | DNA-based | Phase I/II/III | NCT04527081 and 1 more | |||||
Zydus Cadila, Cadila Healthcare Limited | DNA-based | Phase I/II | CTRI/2020/07/026352 | |||||
Unnamed | Multiple Organizations | DNA-based | Preclinical Phase | |||||
Unnamed | BioNet Asia | DNA-based | Preclinical Phase | |||||
Unnamed | University of Waterloo | DNA-based | Preclinical Phase | |||||
Multiple Organizations | Repurposed | Phase III/IV | ![]() | NCT04357028 and 2 more | ||||
Immunitor LLC | Inactivated virus | Phase I/II | ![]() | NCT04380532 | ||||
Multiple Organizations | Modified APC | Phase I/II | ![]() | NCT04386252 and 2 more | ||||
Multiple Organizations | Non-replicating viral vector | Phase I/II/III/IV | ![]() | NCT04324606 and 20 more | ||||
AnGes, Inc., Japan Agency for Medical Research and Development | DNA-based | Phase I/II | NCT04463472 | |||||
Multiple Organizations | Repurposed | Phase II/III/IV | ![]() | NCT04328441 and 29 more | ||||
Multiple Organizations | Inactivated virus | Phase I/II/III | ![]() | NCT04412538 and 2 more | ||||
Multiple Organizations | Protein subunit | Phase I | ![]() | NCT04428073 and 1 more | ||||
Multiple Organizations | Non-replicating viral vector | Phase I/II/III | ![]() | NCT04437875 and 11 more | ||||
Immunovative Therapies, Ltd., Mirror Biologics, Inc. | Other | Phase I/II | ![]() | NCT04441047 | ||||
Multiple Organizations | Repurposed | Phase III | ![]() ![]() | NCT04442048 | ||||
Altimmune, Inc. | Repurposed | Phase II | ![]() | NCT04442230 | ||||
Genexine, Inc. | DNA-based | Phase I/II | NCT04445389 and 1 more | |||||
Multiple Organizations | Repurposed | Phase III/IV | ![]() | NCT04445428 and 2 more | ||||
Inmunotek S.L., BioClever 2005 S.L. | Repurposed | Phase III | ![]() | NCT04452643 | ||||
Fundació Institut Germans Trias i Pujol | Repurposed | Phase N/A | NCT04453488 | |||||
Multiple Organizations | Inactivated virus | Phase I/II/III | ![]() | NCT04471519 and 1 more | ||||
updated | Medigen Vaccine Biologics Corp. | Protein subunit | Phase I/II | ![]() | NCT04487210 and 2 more | |||
Multiple Organizations | Protein subunit | Phase I/II/III | ![]() | NCT04445194 and 3 more | ||||
Multiple Organizations | RNA-based vaccine | Phase I | ![]() | ChiCTR2000034112 | ||||
Merck Sharp & Dohme Corp. | Replicating viral vector | Phase I | ![]() | NCT04498247 | ||||
Adimmune Corporation | Protein subunit | Phase I | ![]() | NCT04522089 | ||||
Oklahoma Medical Research Foundation, University of Oklahoma | Repurposed | Phase I | ![]() | NCT04523246 | ||||
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | Protein subunit | Phase I/II/III | ![]() | NCT04527575 and 1 more | ||||
ReiThera Srl, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani | Non-replicating viral vector | Phase I/II/III | NCT04528641 and 1 more | |||||
Jiangsu Province Centers for Disease Control and Prevention, West China Hospital | Protein subunit | Phase I/II | ![]() | NCT04530656 and 2 more | ||||
University Hospital Tuebingen | Protein subunit | Phase I | ![]() | NCT04546841 | ||||
Multiple Organizations | RNA-based vaccine | Phase I | NCT04566276 | |||||
Entos Pharmaceuticals Inc., Canadian Institutes of Health Research | DNA-based | Phase I | ![]() | NCT04591184 | ||||
ImmunityBio, Inc. | Non-replicating viral vector | Phase I | ![]() | NCT04591717 and 2 more | ||||
Multiple Organizations | Replicating viral vector | Phase I | ![]() | NCT04569383 | ||||
Israel Institute for Biological Research | Replicating viral vector | Phase I/II | NCT04608305 | |||||
Multiple Organizations | Inactivated virus | Phase I/II/III | NCT04530357 and 1 more | |||||
Providence Health & Services, OncoSec Medical Incorporated | DNA-based | Phase I | ![]() | NCT04627675 | ||||
Multiple Organizations | Protein subunit | Phase I/II | ![]() | NCT04636333 and 1 more | ||||
Jiangsu Province Centers for Disease Control and Prevention | Non-replicating viral vector | Phase I | ![]() | NCT04568811 | ||||
City of Hope Medical Center, National Cancer Institute | Replicating viral vector | Phase I | ![]() | NCT04639466 | ||||
GeneOne Life Science, Inc. | DNA-based | Phase I/II | NCT04673149 | |||||
Valneva Austria GmbH, National Institute for Health Research, United Kingdom | Inactivated virus | Phase I/II | ![]() | NCT04671017 | ||||
Cellid Co., Ltd. | Non-replicating viral vector | Phase I/II | NCT04666012 | |||||
Nanogen Pharmaceutical Biotechnology Joint Stock Company | Protein subunit | Phase I/II | NCT04683484 | |||||
Codagenix, Inc | Replicating viral vector | Phase I | ![]() | NCT04619628 | ||||
Altimmune, Inc. | Non-replicating viral vector | Phase I | ![]() | NCT04679909 | ||||
Takeda | Protein subunit | Phase I/II | NCT04677660 | |||||
updated | Health Institutes of Turkey, TC Erciyes University | Inactivated virus | Phase I/II | NCT04691947 and 1 more | ||||
Multiple Organizations | Protein subunit | Phase I/II | ![]() | NCT04702178 | ||||
Multiple Organizations | Protein subunit | Phase I/II | NCT04750343 and 1 more | |||||
Multiple Organizations | DNA-based | Phase I | ![]() | NCT04742842 | ||||
Multiple Organizations | Inactivated virus | Phase I/II | ![]() | NCT04758273 and 1 more | ||||
GlaxoSmithKline | RNA-based vaccine | Phase I | ![]() | NCT04758962 | ||||
Bharat Biotech International Limited | Non-replicating viral vector | Phase I | ![]() | NCT04751682 | ||||
University Medical Center Groningen, Akston Biosciences Corporation | Protein subunit | Phase I/II | ![]() | NCT04681092 | ||||
SK Bioscience Co., Ltd. | Protein subunit | Phase I | NCT04760743 | |||||
Mahidol University, The Government Pharmaceutical Organization | Replicating viral vector | Phase I/II | NCT04764422 | |||||
Providence Therapeutics Holdings Inc. | RNA-based vaccine | Phase I | ![]() | NCT04765436 | ||||
National Institute of Allergy and Infectious Diseases | Non-replicating viral vector | Phase I | ![]() | NCT04776317 | ||||
National Institute of Allergy and Infectious Diseases | RNA-based vaccine | Phase I | ![]() | NCT04776317 | ||||
VBI Vaccines Inc. | Virus Like Particle | Phase I/II | ![]() | NCT04773665 | ||||
Takis, Rottapharm Biotech | DNA-based | Phase I/II | NCT04788459 | |||||
EuBiologics Co.,Ltd | Protein subunit | Phase I/II | NCT04783311 | |||||
Multiple Organizations | Protein subunit | Phase I | ![]() | NCT04784767 | ||||
Meissa Vaccines, Inc. | Replicating viral vector | Phase I | ![]() | NCT04798001 | ||||
Sanofi Pasteur | RNA-based vaccine | Phase I/II | ![]() | NCT04798027 | ||||
Multiple Organizations | Virus Like Particle | Phase I | NCT04818281 | |||||
Jiangsu Rec-Biotechnology Co., Ltd. | Protein subunit | Phase I | ![]() | NCT04818801 | ||||
ModernaTX, Inc. | RNA-based vaccine | Phase I | ![]() | NCT04813796 | ||||
The University of Hong Kong | Replicating viral vector | Phase I | ![]() | NCT04809389 | ||||
new | Daiichi Sankyo Co., Ltd. | RNA-based vaccine | Phase I/II | NCT04821674 | ||||
Merck Sharp & Dohme Corp. | Replicating viral vector | Phase I | ![]() | NCT04569786 |
87 in preclinical development
419 in human trials
Drug CANDIDATES